血吸虫病联合用药的研究进展

Research progress on combined medications for schistosomiasis

目前治疗血吸虫病仍然依赖于吡喹酮单一疗法,尽管吡喹酮可有效杀灭血吸虫成虫,但对幼虫作用弱,且单独使用吡喹酮不能逆转与感染相关的不良病理损害。由于吡喹酮耐药株的出现,亟需寻求可替代的抗血吸虫病药物。当前抗血吸虫病新药研发进展缓慢,但临床前研究和临床试验发现吡喹酮与多种抗疟药物联合应用显示出良好的杀虫效果,与其他辅助药物的联合应用也发挥了协同治疗作用。本文就此方面研究进行综述。

Currently,the praziquantel(PZQ)remains the drug of choice for schistosomiasis treatment.Despite its effectiveness in killing adult schistosomes,PZQ is ineffective for schistosomula,and monotherapy using PZQ cannot reverse the pathological damage associated with the infection.With the emerging PZQ-resistant strains,it is imperative to find out alternatives for PZQ.At present,the research and development of new anti-schistosomiasis drugs is moving slowly,but pre-clinical and clinical trials found that combined medication of PZQ and various antimalarial drugs has shown good schistosomicidal effects.Also,synergistic effects have been exerted by combined use of PZQ and auxiliary drugs in the treatment of schistosomiasis.This article provides a review on the research progress in this field.